FibroBiologics introduces new 2026 equity and incentive compensation plan
FibroBiologics filed a new 2026 Equity and Incentive Compensation Plan to establish rules for granting awards. The document defines key terms for stock options and cash incentives, supporting potential long-term employee retention.
View filing at SEC.gov →